Doximity
DOCS
$19.26
-1.63%
Doximity, Inc. operates a digital platform exclusively for U.S. medical professionals, providing tools for collaboration, secure patient care coordination, virtual visits, medical news, and career management within the Healthcare Information Services industry. The company is the dominant platform in its niche, effectively serving as a professional network and workflow utility for physicians, which creates a significant competitive moat and high user engagement. The current investor narrative is dominated by a severe negative reaction to its latest earnings report, with the stock plunging on news of a sharp slowdown in future revenue growth, forcing a reassessment of its premium valuation against emerging near-term headwinds.…
DOCS
Doximity
$19.26
Related headlines
Investment Opinion: Should I buy DOCS Today?
Rating: Hold. The core thesis is that while Doximity's fundamentals have deteriorated sharply, the extreme valuation compression and strong financial position create a potential value trap that warrants monitoring rather than immediate buying or selling.
Supporting Evidence: The stock trades at a forward P/E of 11.94x, a significant discount to its own history and potentially to peers, suggesting deep value. However, this is countered by collapsing revenue growth of 9.76% YoY and net margin compression of 11.33 percentage points. The company's exceptional gross margin of 89.89% and robust $311.55M TTM free cash flow provide a margin of safety, but the severe -26.23 one-month relative strength indicates powerful negative momentum that may not have fully played out. Analyst sentiment is mixed and sparse, offering no clear target for implied upside.
Risks & Conditions: The two biggest risks are 1) revenue growth failing to stabilize or re-accelerate, and 2) further multiple compression if the market continues to de-rate slowing growth stocks. This Hold rating would upgrade to a Buy if the forward P/E falls below 10x while growth stabilizes above 10%, or if the stock demonstrates a sustained technical reversal above key resistance. It would downgrade to a Sell if revenue growth decelerates further below 5% or if the stock decisively breaks below the $17.15 support level. Currently, the stock appears fairly valued relative to its new, slower growth profile but is undervalued relative to its profitability and cash generation, creating a conflicted picture.
Sign up to view all
DOCS 12-Month Price Forecast
The investment case for DOCS is at an inflection point between deep value and value trap. The catastrophic growth slowdown justifies the massive de-rating, but the resulting valuation (11.94x forward P/E) now prices in a prolonged period of stagnation for a business that still generates 90% gross margins and substantial cash. The neutral stance reflects the high uncertainty around whether growth can stabilize. The stance would upgrade to bullish on evidence of growth re-acceleration or a successful new product cycle, while a breakdown below $17.15 or further guidance cuts would confirm a bearish outlook. The high short interest suggests the potential for a sharp rally on any positive news, but the primary trend remains decisively down.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Doximity's 12-month outlook, with a consensus price target around $25.04 and implied upside of +30.0% versus the current price.
Average Target
$25.04
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$15 - $25
Analyst target range
Analyst coverage for Doximity appears limited in the provided dataset, with only two analysts providing estimates for future EPS and revenue, suggesting institutional coverage may be sparse or the data is incomplete. Without a consensus recommendation or average target price provided in the data, it is impossible to calculate an implied upside or downside, and the sentiment cannot be quantitatively gauged from the available figures. The provided institutional ratings show recent activity, with firms like Canaccord Genuity upgrading from 'Hold' to 'Buy' in February 2026, while others like JP Morgan moved from 'Underweight' to 'Neutral', indicating a mixed but slightly improving sentiment following the steep decline; however, the absence of a clear target range signals high uncertainty and a lack of strong conviction on the stock's near-term path, which is typical following a disruptive earnings event.
Bulls vs Bears: DOCS Investment Factors
The bear case currently holds stronger evidence, anchored by the catastrophic deceleration in revenue growth to 9.76% YoY, which has shattered the stock's premium growth valuation and triggered a 67.54% annual decline. The severe negative momentum and lack of a technical floor further support the bearish near-term outlook. However, the bull case presents a compelling value and quality counter-argument, with the stock now trading at a deeply compressed forward P/E of 11.94x, supported by exceptional profitability (89.89% gross margin) and a fortress balance sheet. The single most important tension in the investment debate is whether the company's dominant market position and strong cash generation can stabilize the business and reignite growth, or if the recent slowdown marks a permanent end to its high-growth phase, justifying its current depressed valuation.
Bullish
- Exceptional Profitability & Cash Generation: The company maintains an outstanding gross margin of 89.89% and generated $311.55M in TTM free cash flow, providing a significant financial cushion. This robust cash flow, coupled with a pristine balance sheet featuring a negligible debt-to-equity ratio of 0.011, offers resilience to weather a growth slowdown and fund future initiatives.
- Dominant Market Position & Moat: As the exclusive digital platform for U.S. medical professionals, Doximity has a deeply entrenched user base and high switching costs. This network effect creates a significant competitive moat within the Healthcare Information Services industry, supporting pricing power and recurring subscription revenue.
- Deeply Compressed Valuation: The stock trades at a forward P/E of 11.94x, a sharp discount to its trailing P/E of 22.23x, suggesting the market has already priced in severe deterioration. With the stock down 67.54% over the past year and trading just 10.6% above its 52-week low, a significant margin of safety exists if growth stabilizes.
- Strong Balance Sheet & Low Financial Risk: With a current ratio of 6.09 and virtually no debt, the company faces no liquidity or solvency risk. This fortress balance sheet provides strategic flexibility to navigate the current downturn without needing external capital, a key advantage over less well-capitalized peers.
Bearish
- Severe Growth Deceleration: Recent quarterly revenue growth has collapsed to just 9.76% YoY, a stark deceleration from prior periods. This sharp slowdown, which triggered the stock's recent plunge, calls into question the company's ability to sustain its previous hyper-growth narrative and justifies a valuation re-rating.
- Persistent Negative Momentum: The stock is in a severe downtrend, down 20.63% over the past month and 67.54% over the past year, with a catastrophic -26.23 relative strength vs. the SPY. This overwhelming technical weakness indicates a complete loss of investor confidence and suggests the selling pressure may not be over.
- Profitability Compression: While still high, the net margin has compressed to 33.27% from 44.60% a year ago. This 11.33 percentage point decline indicates rising costs or pricing pressure are eroding bottom-line efficiency, which could worsen if revenue growth stalls further.
- High Volatility & Market Sensitivity: With a beta of 1.35, DOCS is 35% more volatile than the market, which has magnified its downside during the recent sell-off. This high beta makes the stock susceptible to further declines if broader market sentiment sours, especially for growth-oriented names.
DOCS Technical Analysis
The prevailing price trend is a severe and sustained downtrend, with the stock down 67.54% over the past year, placing it near the bottom of its 52-week range. Trading at a current price of $18.97, it sits just 10.6% above its 52-week low of $17.15, indicating the stock is in deep value territory but also signaling significant fundamental distress and negative momentum that could persist. Recent momentum remains decisively negative, with the stock down 20.63% over the past month and 24.18% over the past three months, confirming the downtrend is accelerating rather than showing signs of reversal; this is starkly illustrated by a catastrophic relative strength of -26.23 versus the SPY over one month. Key technical support is clearly defined at the 52-week low of $17.15, while resistance is far above at the 52-week high of $76.51; a breakdown below $17.15 would signal a complete loss of confidence and likely lead to further declines, while any recovery would face immense overhead supply. With a beta of 1.35, the stock is 35% more volatile than the market, which has magnified its downside during this sell-off and underscores the high risk associated with any position.
Beta
1.35
1.35x market volatility
Max Drawdown
-76.0%
Largest decline past year
52-Week Range
$17-$77
Price range past year
Annual Return
-64.2%
Cumulative gain past year
| Period | DOCS Return | S&P 500 |
|---|---|---|
| 1m | -22.1% | +3.3% |
| 3m | -24.3% | +6.9% |
| 6m | -58.5% | +12.4% |
| 1y | -64.2% | +23.4% |
| ytd | -55.5% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCS Fundamental Analysis
Revenue growth has decelerated markedly, with the most recent quarterly revenue of $185.05 million representing a year-over-year growth of only 9.76%, a significant slowdown from the stronger growth rates seen in prior comparable periods. The subscription segment, constituting $175.38 million of total revenue, remains the core driver, but the overall growth trajectory implies the company's hyper-growth phase may be ending. The company remains highly profitable with a net income of $61.56 million in the last quarter and an exceptional gross margin of 89.89%, though the net margin of 33.27% shows some compression from the 44.60% net margin reported in the year-ago quarter, indicating potential pressure on bottom-line efficiency. The balance sheet is exceptionally strong with minimal financial risk, evidenced by a negligible debt-to-equity ratio of 0.011 and a robust current ratio of 6.09, while the company generates substantial cash, with trailing twelve-month free cash flow of $311.55 million, providing ample internal resources to navigate the current slowdown without external financing needs.
Quarterly Revenue
$185053000.0B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.89%
Latest Quarter
Free Cash Flow
$311547000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCS Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 22.23x, while the forward PE is significantly lower at 11.94x, indicating the market is pricing in a substantial earnings recovery or growth re-acceleration in the coming year. Compared to sector averages, the stock's trailing PE of 22.23x and Price-to-Sales (PS) ratio of 6.76x are not explicitly benchmarked against provided industry averages, but the sharp contraction in the forward multiple suggests the market has already de-rated the stock heavily from its previous premium. Historically, the current trailing PE of 22.23x is near the lower end of its own historical range, which has seen ratios as high as 58.99x and as low as 22.23x in recent quarters; trading at this compressed level suggests the market is pricing in significant fundamental deterioration or growth stagnation, presenting a potential value opportunity if the company can stabilize its business trajectory.
PE
22.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~112x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the severe growth deceleration, with quarterly revenue growth collapsing to 9.76% YoY from much higher prior levels, threatening the core investment thesis. While the company remains profitable, net margin compression from 44.60% to 33.27% indicates rising cost pressures that could further erode earnings if revenue growth does not re-accelerate. The business model, while dominant, is heavily reliant on the U.S. physician market, creating concentration risk if adoption plateaus or a disruptive competitor emerges.
Market & Competitive Risks are pronounced given the stock's 67.54% decline and its high beta of 1.35, which makes it highly sensitive to broader market sell-offs and risk-off sentiment towards growth stocks. The valuation compression risk is significant; the stock has already de-rated from a trailing P/E as high as 58.99x to 22.23x, but further multiple contraction is possible if growth stagnates. The recent news highlights the stock's vulnerability to earnings disappointments, with the latest report causing a sharp plunge and forcing a reassessment of its long-term growth trajectory.
The Worst-Case Scenario involves a continuation of the growth deceleration into negative territory, coupled with further margin compression, leading to consecutive earnings misses. This could trigger a loss of confidence in the company's moat, resulting in the stock breaking below its 52-week low of $17.15. Given the stock's high volatility and negative momentum, a realistic downside from the current price of $18.97 could be a further 35-40% decline, retesting levels near $11-$12, which would represent a total peak-to-trough drawdown exceeding 85%, aligning with its historical max drawdown of -76.03%.
FAQ
The primary risk is fundamental: a continued deceleration or outright decline in revenue growth from the current 9.76% YoY rate, which would invalidate any recovery thesis. Second is valuation risk; despite the steep drop, the stock could experience further multiple compression if classified as a no-growth company. Third is technical/momentum risk, with the stock down 67.54% in a year and showing a -26.23 relative strength versus the market, indicating powerful selling pressure that may not be over. Fourth is market risk, amplified by its high beta of 1.35, making it vulnerable to broad market downturns.
Our 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $22 and $28 as growth stabilizes in the high-single digits and the forward P/E multiple holds around 12x-15x. The Bull Case (25% probability) projects a rally to $35-$45 on successful growth re-acceleration and a sentiment shift. The Bear Case (25% probability) warns of a drop to $14-$18 if growth deteriorates further and the stock breaks key support. The most likely outcome is the Base Case, predicated on the assumption that the company's strong profitability prevents a complete derating but growth does not meaningfully re-accelerate.
DOCS is fairly valued to slightly undervalued relative to its new, slower-growth reality, but was severely overvalued prior to its collapse. The forward P/E of 11.94x is a steep discount to its historical trailing P/E of 22.23x and its peak multiples above 58x, reflecting the market's punishment for its growth deceleration. Compared to profitable SaaS peers, a sub-12x forward earnings multiple for a company with 90% gross margins and no debt is compelling, but only if growth stabilizes. The current valuation implies the market expects minimal future growth and has priced DOCS as a cash cow rather than a growth stock.
DOCS presents a high-risk, high-potential-reward situation that is not suitable for most investors. For deep-value, contrarian investors with a multi-year horizon and high risk tolerance, the current forward P/E of 11.94x and proximity to the 52-week low ($17.15) may offer an attractive entry point, assuming the company's 89.89% gross margins and strong cash flow can support a business turnaround. However, given the severe -67.54% annual decline, collapsing revenue growth (9.76% YoY), and powerful negative momentum, it is a speculative buy at best. The lack of a clear near-term catalyst and high beta of 1.35 make it a challenging hold in the short term.
DOCS is unsuitable for short-term trading due to its high volatility (beta 1.35), negative momentum, and lack of near-term positive catalysts. The extreme price swings, exemplified by the 24.18% decline over the past three months, make timing entries and exits exceptionally difficult. For long-term investors (3-5 year horizon), the current valuation may present a compelling entry point if one believes in the durability of the company's niche moat and its ability to eventually re-accelerate growth. The strong balance sheet and cash flow provide a margin of safety for patient capital. A minimum holding period of 2-3 years is suggested to allow for a potential operational turnaround and for market sentiment to recover.